FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer By Ogkologos - May 13, 2026 242 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Updated Nutrition Facts Label Reflects Science on Diet and Health, including... May 19, 2020 Stopping TKI Treatment Is Safe, Improves Quality of Life for Some... December 15, 2020 Why the Bone Marrow Registry Needs More Diverse Donors and How... March 30, 2021 FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or... May 9, 2025 Load more HOT NEWS First-Line Pembrolizumab Continues to Show Durable Clinical Benefit After 5 Years... EMA’s Safety Committee Has Concluded That the Benefits of Ifosfamide Solutions... ESMO Calls for Cancer Care Integration in EU Global Health Resilience... Inequalities cause 2,000 extra cancer cases in Wales
